NLS Pharmaceutics Ltd (NLSP)
3.365
+0.08
(+2.28%)
USD |
NASDAQ |
Nov 21, 16:00
3.17
-0.20
(-5.79%)
After-Hours: 20:00
NLS Pharmaceutics Enterprise Value: 14.00M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 14.00M |
| November 20, 2024 | 13.71M |
| November 19, 2024 | 13.29M |
| November 18, 2024 | 13.60M |
| November 15, 2024 | 13.10M |
| November 14, 2024 | 13.90M |
| November 13, 2024 | 14.36M |
| November 12, 2024 | 16.04M |
| November 11, 2024 | 16.31M |
| November 08, 2024 | 16.19M |
| November 07, 2024 | 16.99M |
| November 06, 2024 | 16.76M |
| November 05, 2024 | 16.57M |
| November 04, 2024 | 17.91M |
| November 01, 2024 | 14.90M |
| October 31, 2024 | 15.01M |
| October 30, 2024 | 15.89M |
| October 29, 2024 | 16.92M |
| October 28, 2024 | 16.84M |
| October 25, 2024 | 17.11M |
| October 24, 2024 | 17.41M |
| October 23, 2024 | 18.73M |
| October 22, 2024 | 19.63M |
| October 21, 2024 | 12.92M |
| October 18, 2024 | 14.26M |
| Date | Value |
|---|---|
| October 17, 2024 | 13.96M |
| October 16, 2024 | 13.71M |
| October 15, 2024 | 12.95M |
| October 14, 2024 | 12.50M |
| October 11, 2024 | 12.16M |
| October 10, 2024 | 11.66M |
| October 09, 2024 | 7.134M |
| October 08, 2024 | 7.349M |
| October 07, 2024 | 7.096M |
| October 04, 2024 | 6.904M |
| October 03, 2024 | 6.875M |
| October 02, 2024 | 6.997M |
| October 01, 2024 | 7.255M |
| September 30, 2024 | 7.103M |
| September 27, 2024 | 7.255M |
| September 26, 2024 | 7.021M |
| September 25, 2024 | 7.363M |
| September 24, 2024 | 7.677M |
| September 23, 2024 | 7.517M |
| September 20, 2024 | 8.239M |
| September 19, 2024 | 7.578M |
| September 18, 2024 | 7.574M |
| September 17, 2024 | 7.831M |
| September 16, 2024 | 7.536M |
| September 13, 2024 | 7.498M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
4.661M
Minimum
May 20 2022
70.97M
Maximum
Mar 12 2021
21.23M
Average
17.41M
Median
Oct 24 2024
Enterprise Value Benchmarks
| AC Immune SA | 137.84M |
| CRISPR Therapeutics AG | 2.015B |
| Addex Therapeutics Ltd | 4.450M |
| Molecular Partners AG | 28.94M |
| MoonLake Immunotherapeutics | 2.784B |
Enterprise Value Related Metrics
| Earnings Yield | -200.3% |